Study of Human Papillomavirus infection in the state of Guaira, Venezuela
Keywords:
Infection, Detection, Human Papillomavirus (HPV), CervixAbstract
This study aims to contribute to the national data, through HPV screening through molecular biology tests and compares its effectiveness with respect to the Pap smear. 119 female patients were included, from whom the corresponding samples were taken for molecular HPV detection and cytological evaluation of the cervix. After the quality evaluation, 2 patients were excluded for not meeting the criteria, leaving 116 samples included for the study. DNA isolation as well as HPV detection and typing were performed with the commercial kits Wizard Genomic DNA Purification Kit (Promega®) and Seeplex HPV4A ACE (Seegene, Korea) respectively following the specifications from the commercial companies. The average age of the patients was 39.39 ± 13.255, with respect to the cytological diagnosis it could be observed that moderate non-specific inflammation was the most frequent diagnosis (28.4%) followed by mild non-specific inflammation (23 ,3%); LIEbg were reported in 8.6% of the cases evaluated. 30% of the patients tested positive for HPV infection, with HR genotypes being the most frequent (80%) followed by co-infection of genotype 16 with other HR (11.4%). A relationship was observed between the inflammatory cytological diagnosis and viral infection, which is why follow-up of this group of women is suggested since this is associated with progression towards LIEbg and subsequent development of cervical cancer.
References
Escudero Elizabeth, Carrera Jelitza, Banegas Alison, Turaren Lila, Domo Ivan, Ontaneda Joao, et al. Revisión bibliográfica: detección temprana del Cáncer de cuello uterino. Brazilian Journal of Health Review. 2023 Jan 20;6(1):1570–80.
Fernandes A, Pérez MM, Ávila M, Fuenmayor J, Karolinski A, Hoegl J. Current perspective on cervical cancer prevention in Venezuela. Assessment through a survey. Rev Obstet Ginecol Venez. 2022 Jul 1;82(3):340–9.
von Karsa L, Arbyn M, De Vuyst H, Dillner J, Dillner L, Franceschi S, et al. European guidelines for quality assurance in cervical cancer screening. Summary of the supplements on HPV screening and vaccination. Vol. 1, Papillomavirus Research. Elsevier; 2015. p. 22–31.
Hernández-Aguado JJ, de La Fuente-Valero J, Ramírez Mena M, Ortega-Medina L, Vidart Aragón JA, Galán JC. Comparative pilot study about HPV test with partial genotyping in primary screening versus other strategies for cervical cancer population screening, CRYGEN 16/18 study. Enferm Infecc Microbiol Clin. 2023 May 1;41(5):262–8.
Verdessi A, Perán F, Espinosa R, Verdessi A, Perán F. CIMEL Ciencia e Investigación Médica. CIMEL Ciencia e Investigación Médica Estudiantil Latinoamericana. 2006;11(2):78–82.
Falcón-Córdova Diana, Carrero Yenddy. Situación actual de la infección por Virus del Papiloma Humano (VPH) asociado a lesiones cervicales en mujeres del ecuador. Revisión Sistemática Current situation of Human Papilloma Virus (HPV) associated with cervical injuries in women of Ecuador: Systematic Review. Revisión Sistemática Virología Kasmera [Internet]. 2021;49(1):49133050. Available from: https://doi.org/10.5281/zenodo.4587242
Allende-Perez S, Dominguez-Ocadio G, Velez-Salas V, Isla-Ortiz D, Peña-Nieves A, Verastegui E. Snapshot of symptoms of advanced cervical cancer patients referred to the palliative care service in a cancer center in Mexico. . Int J Gynaecol Obstet. 2021 May;153(2):335–9.
Nayar R, Wilbur D. The Pap Test and Bethesda 2014. Acta Cytol. 2015;59(2):121–32.
Sara García D. Detection of HPV in women with no cellular alterations detected in uterine cytology in Castilla y León, population study. Vol. 85, Ginecol Obstet Mex. 2017.
Bosch FX, Broker TR, Forman D, Moscicki AB, Gillison ML, Doorbar J, et al. Comprehensive Control of Human Papillomavirus Infections and Related Diseases. Vaccine. 2013 Dec;31:H1–31.
Trigo-Daporta M, García-Campello M, Pérez-Ríos M, Santiago-Pérez MI, Fernández-Rodríguez E, Fernández-Rodríguez E, et al. High-risk human papillomavirus in GaliciSpain: Prevalence and evaluation of the sample representativeness. Scand J Infect Dis. 2014;46:737–44.
Orrego PA, Trujillo P, Cirujano M, Patóloga MA, Ruiz-Leud A, Bazán-Ruiz S, et al. Trabajos Originales.
Josipa Skelin, Ivan Sabol, Vjekoslav Tomaić. Do or Die: HPV E5, E6 and E7 in Cell Death Evasion. Pathogens. 2022;9(11):1027.
Hemmat N, Bannazadeh Baghi H. Association of human papillomavirus infection and inflammation in cervical cancer. Pathog Dis. 2019;77(5).
Sadri Nahand J, Moghoofei M, Salmaninejad A, Bahmanpour Z, Karimzadeh M, Nasiri M, et al. Pathogenic role of exosomes and microRNAs in HPV-mediated inflammation and cervical cancer: A review. Vol. 146, International Journal of Cancer. Wiley-Liss Inc.; 2020. p. 305–20.
Gutiérrez C, Peña C, Zamorano D. Medidas de autocuidado y genotipificación del virus papiloma humano en mujeres de la unidad de patología cervical, Hospital Carlos Van Buren. Rev Chil Salud Pública. 2016;20(1):19–28.
Urdaneta J, Baabel N, Maggiolo I, COntreras A. Genotipificación del Virus del Papiloma Humano en mujeres en edad reproductiva del estado Zulia, Venezuela. VITAE. 2018;75.
Amézquita M, Silva GC, Restrepo DA, Ibata LM, Niño R, Bustacara M, et al. Budget impact analysis of primary screening with the HPV test and genotyping against conventional cytology in Colombia. Biomedica. 2022;42(2):290–301.
Sankaranarayanan R, Nene BM, Shastri SS, Jayant K, Muwonge R, Budukh AM. HPV screening for cervical cancer in rural India. N Eng J Med. 2009;360:1385–94.
Amézquita M, Silva GC, Restrepo DA, Ibata LM, Niño R, Bustacara M, et al. Budget impact analysis of primary screening with the HPV test and genotyping against conventional cytology in Colombia. Biomedica. 2022;42(2):290–301.
Downloads
Additional Files
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Multidisciplinary & Health Education Journal
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
